{"prompt": "['< 30 to < 20', 'NE', '100', 'Unequivocal progression', 'Any', 'PD', '30', '< 30 to', '< 20', 'NE', '> 20 from nadir', 'Any', 'Any', 'PD', 'NE', 'Present/Absent/NE', 'Absent', 'NE', 'a. Decreases assessed relative to baseline, including measurable lesions only', 'b. In exceptional circumstances, unequivocal progression in non-target lesions may be accepted as disease progression', 'Note: Patients with a global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time should be reported as \"symptomatic', 'deterioration. Every effort should be made to document the objective progression even after discontinuation of treatment.', '49']['7.1.4.2 Survival', 'Survival will be assessed throughout treatment as well as in the post-treatment period and', \"long-term follow-up period until the patient's withdrawal of consent or loss to follow up,\", 'death, or study termination.', '7.1.4.3 Tumor Tissue Collection and Correlative Studies Blood Sampling', '7.1.4.3.1 Tumor Tissue Collection', 'Tumor tissue will be collected prior to trial enrollment and allotment in the form of archival', 'tissue. If archival tissue is not available, tumor biopsy must be obtained prior to the first', 'dose. Subjects must have recovered adequately from the biopsy prior to starting therapy.', 'Tissue will be obtained during nephrectomy and will serve as the post-treatment specimen.', 'Any obtained tissues will be handled as follows:', 'RNAlater for RNA stabilization and tissue storage', 'Formalin-fixed paraffin-embedded (FFPE) block with one cut H&E stained', 'slide', 'Liquid nitrogen frozen tissue in cryo-preservation vials', 'All collected tissues are stabilized and stored in -80\u00b0C freezers (RNAlater stabilized, OCT', 'embedded, short term storage) or the vapor phase of a liquid nitrogen freezer (long term', 'storage) in single use aliquots. All FFPE tissue blocks are stored in a climate-controlled', 'storage room that is temperature (less than 27\u00b0C) and humidity controlled.', 'Tissue will be evaluated for assessment of mutations and/or immune markers including PD-', '1/PD-L1 and other relevant biomarkers (e.g. tumor infiltrating lymphocytes, T- cell', 'repertoire, RNA signature profiles). When sufficient quantities of fresh tissue are available, it', 'will also be dissociated and flow cytometry will be used to determine the phenotypic', 'characteristics of cell populations in the tumor microenvironment. Tissue will be preserved', 'for future exploratory studies including genomic profiling.', '7.1.4.3.2 Correlative Studies Blood Sampling', 'Correlative peripheral blood samples will be collected prior to study drug allotment, on Cycle', '1 Day 1 of each cycle, on Cycle 1 Day 8 to assess for any immune-related changes occurring', 'in the immediate period following checkpoint inhibitor exposure, and in the post-treatment', 'period (both pre- and post-nephrectomy) as expanded in the Trial Flow Chart. Approximately', '60 mL of peripheral blood will be collected at each time point. The samples will be stored in', '-80\u00b0C freezers until analysis. Stool sample for microbiome analysis will be collected at', 'baseline, and post-treatment phase within the 14 days after the last dose of lenvatinib.', 'Analysis may include but is not limited to:', '50']['Circulating tumor DNA (ctDNA) to explore genetic alterations that are present are', 'baseline and/or emerge during treatment', 'Analysis of peripheral blood mononuclear cells (PBMCs) to assess for', 'phenotypic/functional changes in T-cells or myeloid markers during and after', 'treatment', 'Nuclear acid analysis for gene expression profiling', 'Stool sample for microbiome analysis', 'Shipping and handling instructions', 'After appropriate processing, the blood samples, tissue blocks, slides or frozen tissue samples', 'will be sent to:', 'Kissick Laboratory', '1462 Clifton Rd, Room 420', 'Atlanta, Georgia, 30322', 'ph: 617 259 8364', 'email: haydn.kissick@emory.edu', 'On the day that the specimens are to be shipped, notify Dr. Haydn Kissick of the pending', 'specimen shipments. Include the Fed-Ex tracking number in the email.', 'Research blood contact Information:', 'Kissick Laboratory', 'ph: 617 259 8364', 'email: haydn.kissick@emory.edu', '7.1.5 Other Procedures', '7.1.5.1 Local Registration/Enrollment Procedures', '7.1.5.1.1 Registration', 'Study personnel will notify Winship Central Subject Registration (WCSR) by email at', 'winshipcsr@emory.edu once subject has been consented for a trial. Email notification must', 'be done within 24 hours after consent has been obtained and it will include scanned copies', 'of:', 'Signed patient consent form', 'HIPAA authorization form', 'Emory Research Management System (ERMS; https://erms.emory.edu)', 'Enrollment Fax Cover', '51']\n\n###\n\n", "completion": "END"}